Panacea Biotec Pharma Limited Gliclazide Export Data — India (DGFT 2022–2026)

Name: Panacea Biotec Pharma Limited Gliclazide Export Records India — #2 Exporter, 50 Shipments, $2.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Gliclazide

India Pharmaceutical Trade Intelligence

$300.8M238 Suppliers109 CountriesHS 30049099

ExportsIndia → HUNGARY29.3%India → NETHERLANDS29.2%

ImportsUNITED KINGDOM → India$1.0M BULGARIA → India$261.6K

#1 Supplier: MYLAN LABORATORIES #1 Buyer: MYLAN HUNGARY

Panacea Biotec Pharma Limited — Gliclazide Exporter #2 | $2.5M Trade Value | TransData Nexus | TransData Nexus

Panacea Biotec Pharma Limited — Gliclazide Exporter Profile

Indian Pharmaceutical Exporter · #2 for Gliclazide · $2.5M export value · DGFT Verified

Panacea Biotec Pharma Limited is the #2 Indian exporter of Gliclazide with $2.5M in export value and 50 verified shipments. Panacea Biotec Pharma Limited holds a 0.8% market share in Gliclazide exports across 5 countries. The company exports 13 pharmaceutical products worth $23.9M across 9 therapeutic categories.

Panacea Biotec Pharma Limited — Gliclazide Export Profile: Buyers & Destinations

Panacea Biotec Pharma Limited Gliclazide export treemap — buyers and destination countries | TransData Nexus

Where Does Panacea Biotec Pharma Limited Export Gliclazide?

Country	Value	Shipments	Share
VIETNAM, DEMOCRATIC REP. OF	$759.7K	17	44.3%
THAILAND	$367.5K	9	21.4%
VIETNAM	$250.0K	5	14.6%
VIETNAM DEMOCRATIC REP. OF	$200.0K	4	11.7%

Who Are the Top Buyers of Gliclazide from Panacea Biotec Pharma Limited?

Buyer	Country	Value	Orders
DANANG PHARMACEUTICAL MEDICAL EQUIP	VIETNAM, DEMOCRATIC REP. OF	$959.7K	21
BIOGENETECH CO. LTD,	THAILAND	$167.5K	5
M S BIOGENETECH CO LIMITED	THAILAND	$150.0K	3
SOHACO TRADING AND PHARMACEUTICAL	VIETNAM	$100.0K	2
DANANG PHARMACEUTICAL MEDICAL EQUIP MENTJOINT STOCK CO	VIETNAM	$100.0K	2
M S DANANG PHARMACEUTICAL MEDICAL EQUIPMENTJOINT STOCK CO	VIETNAM	$50.0K	1
M/S. BIOGENETECH CO. LTD,	THAILAND	$50.0K	1
ASIA PHARMA CO LTD	MONGOLIA	$45.1K	1
RIGHT & BRIGHT INTERNATIONAL COMPAN	MYANMAR	$28.7K	4
M S ASIA-PHARMA CO LTD	MONGOLIA	$19.4K	1

Panacea Biotec Pharma Limited supplies Gliclazide to 15 buyers globally. The largest buyer is DANANG PHARMACEUTICAL MEDICAL EQUIP (VIETNAM, DEMOCRATIC REP. OF), followed by BIOGENETECH CO. LTD, (THAILAND) and M S BIOGENETECH CO LIMITED (THAILAND). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Gliclazide Formulations Does Panacea Biotec Pharma Limited Export?

Product Description / Formulation	Value	Shipments
GLIZYM M TABLETS EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80 MG + METFORMINHYDROCHLORIDE IP 500 MG B/N.01823001 B/	$150.0K	3
GLIZYM M TABLETS (EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80 MG + METFORMINHYDROCHLORIDE IP 500 MG) B/N.18423044 TO	$137.8K	3
GLIZYM M TABLETS EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80 MG + METFORMINHYDROCHLORIDE IP 500 MG B/N.18423020 TO	$100.0K	2
GLIZYM M TABLETS (EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80 MG + METFORMINHYDROCHLORIDE IP 500 MG) B/N.18423035 TONOS	$71.8K	3
GLIZID M TABLETS (EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80 MG + METFORMINHYDROCHLORIDE IP 500 MG) B/N.01824001 &	$67.5K	3
GLIZYM M TABLETS EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80 MG METFORMINHYDROCHLORIDE IP 500 MG B N 18422018 1	$50.0K	1
GLIZYM M TABLETS EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80MG METFORMIN HYDROCHLORIDE IP 500MG B N 18422022 TO 1	$50.0K	1
GLIZYM M TABLETS EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80 MG + METFORMINHYDROCHLORIDE IP 500 MG B/N.18423017, 1	$50.0K	1
GLIZID M TABLETS (EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80 MG + METFORMINHYDROCHLORIDE IP 500 MG) B/N.01823003 M/	$50.0K	1
GLIZYM M TABLETS (EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP 80 MG + METFORMINHYDROCHLORIDE IP 500 MG) B/N.18423023 TO	$50.0K	1

Panacea Biotec Pharma Limited exports 37 distinct Gliclazide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is GLIZYM M TABLETS EACH UNCOATED TABLET CONTAINS GLICLAZIDE BP with 3 shipments worth $150.0K.

How Does Panacea Biotec Pharma Limited Compare to Nearest Gliclazide Exporters?

Exporters ranked immediately above and below #2 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
10	BAL PHARMA LIMITED	$2.6M	136	17	$18.8K
11	TORRENT PHARMACEUTICALS LIMITED	$2.5M	83	2	$30.7K
2	PANACEA BIOTEC PHARMA LIMITED ★	$2.5M	50	5	$50.0K
13	INVENTIA HEALTHCARE LIMITED	$2.0M	134	6	$14.8K
14	ALKEM LABORATORIES LIMITED	$2.0M	68	2	$29.2K

Panacea Biotec Pharma Limited ranks #2 among 238 Indian Gliclazide exporters. Average shipment value of $50.0K compared to the market average of $287.6K. The closest competitors by value are BAL PHARMA LIMITED and TORRENT PHARMACEUTICALS LIMITED.

Which Indian Ports Ship Gliclazide Exports?

Port	Shipments	% Share
NHAVA SHEVA SEA (INNSA1)	439	11.5%
SAHAR AIR	375	9.8%
JNPT/ NHAVA SHEVA SEA	323	8.4%
SAHAR AIR CARGO ACC (INBOM4)	247	6.4%
DELHI AIR	229	6.0%
JNPT	203	5.3%
DELHI AIR CARGO ACC (INDEL4)	165	4.3%
CMA CGM LOGISTICS PARK ICD	103	2.7%

Geopolitical & Trade Policy Impact on Panacea Biotec Pharma Limited's Gliclazide Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Panacea Biotec. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight charges and potential delays. These maritime disruptions are particularly concerning for time-sensitive pharmaceutical shipments, as extended transit times and congestion elevate the risk of cold-chain failures for vaccines and biologics. (pharmaceuticalcommerce.com)

In the United States, recent tariff implementations have introduced uncertainties for Indian exporters. While health products have been exempt from U.S. tariffs, there is growing concern that this exemption may not be permanent. The potential imposition of tariffs on pharmaceutical imports could impact Panacea Biotec's profitability, given the company's significant export volume to the U.S. market. (lemonde.fr)

Conversely, the U.S.-China trade tensions have opened avenues for Indian pharmaceutical companies to capture market share previously held by Chinese manufacturers. This shift presents an opportunity for Panacea Biotec to expand its footprint in the U.S. market, provided it can navigate the evolving regulatory and trade environment effectively.

In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement for exporters. The recent GMP non-compliance issue at Panacea Biotec's Baddi facility underscores the importance of adhering to stringent EU regulations. Addressing these compliance challenges promptly is essential to maintain and grow the company's presence in European markets.

Panacea Biotec Pharma Limited — Regulatory Compliance & Quality Standards

The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the U.S. FDA and the European Medicines Agency (EMA) enforcing stringent quality standards. For Indian exporters, maintaining compliance with these standards is paramount to ensure uninterrupted market access.

Panacea Biotec's recent GMP non-compliance at its Baddi facility highlights the critical need for robust quality management systems. The company has committed to implementing comprehensive corrective and preventive actions and plans to request a re-inspection to reinstate its GMP certificates. (prysm.fi) Proactive measures in quality assurance will be vital for Panacea Biotec to rebuild trust with regulatory bodies and international clients.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Gliclazide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Panacea Biotec Pharma Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 50 individual customs records matching Panacea Biotec Pharma Limited exporting Gliclazide, covering 37 formulations to 7 countries via 15 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 109+ countries, 643+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Gliclazide

Gliclazide

Panacea Biotec Pharma Limited — Gliclazide Exporter Profile

Panacea Biotec Pharma Limited — Gliclazide Export Profile: Buyers & Destinations

Where Does Panacea Biotec Pharma Limited Export Gliclazide?

Who Are the Top Buyers of Gliclazide from Panacea Biotec Pharma Limited?

What Is India's Total Gliclazide Export Value and How Much Does Panacea Biotec Pharma Limited Contribute?

What Is the Average Shipment Value for Panacea Biotec Pharma Limited's Gliclazide Exports?

How Does Panacea Biotec Pharma Limited Compare to Other Indian Gliclazide Exporters?

What Gliclazide Formulations Does Panacea Biotec Pharma Limited Export?

How Does Panacea Biotec Pharma Limited Compare to Nearest Gliclazide Exporters?

Which Indian Ports Ship Gliclazide Exports?

Geopolitical & Trade Policy Impact on Panacea Biotec Pharma Limited's Gliclazide Exports

Panacea Biotec Pharma Limited — Regulatory Compliance & Quality Standards

About Panacea Biotec Pharma Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Gliclazide Export Data from Panacea Biotec Pharma Limited

Gliclazide Stats

Company Overview

Top Products by Panacea Biotec Pharma Limited

Related Analysis

Need Detailed Export Data?

Data Source